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Coronary endothelial dysfunction is the earliest abnor-
mality in the development of coronary atherosclerosis
and is also independently associated with future cardiac
events. Quantification of myocardial blood flow (MBF)
can assist in the diagnosis of diffuse coronary artery
disease (CAD), heart failure and microvascular disease
[1, 2]. In the absence of coronary stenoses, a reduced
coronary flow reserve (CFR) reflects dysfunction of the
coronary microcirculation.
Positron emission tomography (PET) plays an important
role in the assessment of MBF due to four major character-
istics: (1) high sensitivity, (2) excellent temporal resolution,
(3) the possibility to label molecules without altering their
chemical properties and (4) the short half-life of isotopes. The
most common method of quantifying MBF involves the
acquisition of dynamic images with the cyclotron-produced
radiopharmaceuticals
13N-ammonia and
15O-water. An alter-
native method is the generator-produced
82Rb.
In this issue of the European Journal of Nuclear Medicine
and Molecular Imaging, Yoshinaga and colleagues present
some interesting data comparing the quantitative analysis of
coronary endothelial function with
82Rb and
15O-water PET
[3]. MBF was assessed at rest and during a cold pressor test
(CPT) with
82Rb and
15O-water PET in controls and
smokers. They found a reduced CPT to rest ratio in smokers
compared with controls for both radiopharmaceuticals. They
concluded that
82Rb is a reliable method in comparison to
15O-water PET and that
82Rb may be applicable for risk
assessment in subjects with coronary risk factors.
The usefulness of
82Rb is proven in this study; however,
the study included in total 19 subjects, and there will be a
need for studies with larger sample sizes. A wide pallet of
pathological disorders like hyperlipidaemia, hypertension,
diabetes and smoking attenuate the vasomotor response to
NO and reveals the widespread distribution of underlying
causes that can result in endothelial dysfunction. In other
words, MBF assessment provides a way to document how
risk factors translate into measurable damage to the
coronary circulation.
In my opinion, it is time to get MBF PET ready for the
future, because of the open access to
82Rb now in Europe.
The use of
82Rb would give advantages compared to
13N-
ammonia and
15O-water PET: no need for a cyclotron, 24-h/
day access, fast acquisition protocols allowing high through-
put, evaluation of stunning by using rest and stress gating
modality and a better visual quality compared to
15O-water.
Also absolute quantification of MBF is possible with
82Rb
and validated [4, 5] and the important parameter of CFR for
prognosis can be calculated [6]. Due to the wide range of the
82Rb positron, the resolution is reduced. An important issue
of concern is the cost-effectiveness of
82Rb, especially
compared to the widely used SPECT technique. The
82Rb
generator needs to be replaced every 4–6 weeks, rendering
this technique relatively expensive, with a price in the region
of 25,000 euros. Industry should put maximal effort into
reducing the price of the generator, so that
82Rb may finally
facilitate a breakthrough of cardiac PET myocardial perfu-
sion imaging (MPI) for routine clinical practice in Europe.
The first studies on the clinical utility of
82Rb MPI were
reported almost 25 years ago [7], and accurate data of
82Rb
MPI are available in the literature linked to outcomes [8, 9].
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82Rb is now widely available in the USA, this
tracer is moderately available in Europe; however, a dawn
is coming. Industrial
82Rb supply for Europe is growing and
may lead to a wider implementation of
82Rb. Nevertheless,
and although the use of
82Rb has been already described in a
number of reports in the literature, the merit of the present
study is that it encourages us to benefit from the substantial
superiority of the PET technique for instance over SPECT,
resulting in good image quality even in obese patients. The
superiority over SPECT can be expected regarding accuracy,
study duration, staff radiation exposure, reduced patient
dose, patient discomfort and potentially economic benefit.
These are all important implications, which may not have
been fully appreciated in Europe so far. A clinical role of
MBF PET should be highlighted now, because of the easier
access to
82Rb.
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